激发改革活力 聚焦健康需求

Core Insights - The article highlights the transformation of Northeast Pharmaceutical over the past seven years, emphasizing its partnership with the Liaoning Fangda Group, which has led to significant reforms and resource restructuring, resulting in a revitalized company focused on high-quality development [1] Quality Commitment - Northeast Pharmaceutical has maintained a strong commitment to quality, exemplified by its successful passing of an international audit for dietary supplements, achieving a "zero defect" status [2] - The company has invested nearly 300 million yuan in social contributions over the past seven years, focusing on industry poverty alleviation and rural revitalization [2] System Activation - The company has established a robust suggestion system that encourages employees to propose improvements, resulting in over 1,300 suggestions received in the past year, with more than 900 implemented [3] - An effective incentive mechanism has been created, rewarding employees with over 27 million yuan for various innovations in the past three years [3] Risk Management and Innovation - Following its integration into Fangda Group, Northeast Pharmaceutical has adopted advanced management practices, establishing a comprehensive risk control mechanism for major contracts [4] - The company has significantly increased its R&D investment, focusing on identifying high-potential new drug projects through a multi-faceted approach, including independent and collaborative development [4][5] - Northeast Pharmaceutical has developed a robust R&D system in cutting-edge technologies such as TCR-T and CAR-T, positioning itself among the leaders in cell therapy and opening new avenues in biopharmaceutical innovation [5]